Aktuellt
SENASTE
Redeye is relieved to see that the CHMP reiterates its positive opinion of Lecanemab/Leqembi with no changes, and thus that the European Commission can resume its decision-making process. We don’t expect any more hurdles in the approval process and think that a positive share price reaction is warranted.
LÄS MER
